bims-netuvo Biomed News
on Nerves in tumours of visceral organs
Issue of 2025–02–16
fourteen papers selected by
Maksym V. Kopanitsa, Charles River Laboratories



  1. Cancer Metastasis Rev. 2025 Feb 11. 44(1): 31
      Cellular plasticity and the ability to avoid terminal differentiation are hallmarks of cancer. Here, we review the evidence that tumor cells themselves can take on properties of neurons of the central nervous system, which can regulate tumor growth and metastasis. We discuss recent evidence that axon guidance molecules and regulators of electrical activity and synaptic transmission, such as ion channels and neurotransmitters, can drive the oncogenic and invasive properties of tumor cells from a range of cancers. We also review how FDA-approved treatments for neurological disorders are being tested in pre-clinical models and clinical trials for repurposing as anti-cancer agents, offering the potential for new therapies for cancer patients that can be accessed more quickly.
    Keywords:  Axon guidance; Drug repurposing; Ion channels; Metastasis; Neuron; Synapse
    DOI:  https://doi.org/10.1007/s10555-025-10249-3
  2. Clin Cancer Res. 2025 Feb 12.
      Schwannomatoses (SWN) are distinct cancer predisposition syndromes caused by germline pathogenic variants in the genes NF2, SMARCB1, or LZTR1. There is significant clinical overlap between these syndromes with the hallmark of increased risk for cranial, spinal and peripheral schwannomas. Neurofibromatosis type 2 was recently renamed as NF2-related SWN and is the most common SWN syndrome with increased risk for bilateral vestibular schwannomas, intradermal schwannomas, meningiomas and less commonly ependymoma. SMARCB1-related SWN is a familial SWN-syndrome associated with peripheral and spinal schwannomas and an increased risk for meningiomas and malignant peripheral nerve sheath tumors, even in the absence of radiation. These individuals do not develop bilateral vestibular schwannomas. Finally, patients with LZTR1-related SWN typically present with peripheral schwannomas, and unilateral vestibular schwannomas have been reported. The following perspective is intended to highlight the clinical presentation and international tumor surveillance recommendations across these SWN-syndromes.
    DOI:  https://doi.org/10.1158/1078-0432.CCR-24-3278
  3. Cancer Res. 2025 Feb 11.
      Brain metastasis occurs in about 50% of all women with metastatic HER2+ breast cancer and confers poor prognosis for patients. Despite effective HER2-targeted treatments of peripheral HER2+ breast cancer with trastuzumab and HER2 inhibitors, limited brain permeability renders these treatments inefficient for HER2+ breast cancer brain metastasis (BCBM). The scarcity of suitable patient-derived in vivo models for HER2+ BCBM has curtailed the study of molecular mechanisms that promote growth and therapeutic resistance in brain metastasis. Here, we generated and characterized a luminal B HER2+ BCBM cell model (BCBM94) isolated from a patient HER2+ brain metastasis. Repeated hematogenic xenografting of BCBM94 consistently generated BCBM in mice. The clinical receptor tyrosine kinase inhibitor (RTKi) lapatinib blocked phosphorylation of all ErbB receptors (ErbB1-4) and induced the intrinsic apoptosis pathway in BCBM94. Neuregulin-1 (NRG1), an ErbB3/ErbB4 ligand that is abundantly expressed in the brain, abrogated lapatinib-induced apoptosis in HER2+ BCBM94 and BT474 models. ErbB3 signaling pathways that involved PI3K-AKT and the phosphorylation of BAD at serine 136 to prevent apoptosis were essential for NRG1-induced survival. High throughput RTKi screening identified the brain-penetrant pan-ErbB inhibitor poziotinib as a highly potent compound that reduced cell viability in HER2+ BCBM in the presence of NRG1. Two weeks of poziotinib treatment successfully ablated BCBM94 and BT474 HER2+ brain tumors in vivo. In conclusion, this study established a patient-derived HER2+ BCBM model and identified poziotinib as highly efficacious RTKi with excellent brain penetrability that eliminated HER2+ BCBM.
    DOI:  https://doi.org/10.1158/0008-5472.CAN-24-1793
  4. J Clin Med. 2025 Jan 28. pii: 864. [Epub ahead of print]14(3):
      Background/Objectives: Docetaxel is a cytotoxic agent for the treatment of breast cancer, and its toxicities include peripheral neuropathy (PN). This study evaluated the ability of frozen sock (FS) treatment to prevent docetaxel-induced PN by performing nerve conduction study (NCS). Methods: From October 2017 to October 2018, 48 patients who had invasive carcinoma and were planned for docetaxel treatment every three weeks were evaluated. Patients wore a FS on the right foot, and the left foot was not protected by the FS during docetaxel infusion. Motor and sensory NCS as well as nail and skin toxicities were assessed. Results: The amplitude and velocity of the motor and sensory nerves significantly decreased after three months in both feet. Before and after three months of chemotherapy, the compound motor action potentials (CMAPs) for the right peroneal nerve were 7.64 ± 2.42 and 6.81 ± 2.21 mV, respectively (p < 0.001), and 7.13 ± 2.41 and 5.90 ± 2.24 mV, respectively (p < 0.001), for the left peroneal nerve. Reductions in the CMAP amplitude of the peroneal nerve were significantly lower in the right foot compared to the left foot (-9.58 vs. -16.8, p = 0.043). Application of the FS did not significantly decrease the overall incidence of skin and nail toxicity compared with the left foot during the study period (all p > 0.05). Conclusions: Docetaxel induced motor and sensory PN, but the use of a FS resulted in a smaller reduction in peroneal nerve amplification three months after the end of chemotherapy.
    Keywords:  breast neoplasms; chemotherapy; docetaxel; peripheral neuropathy
    DOI:  https://doi.org/10.3390/jcm14030864
  5. Brain Res Bull. 2025 Feb 06. pii: S0361-9230(25)00047-4. [Epub ahead of print]222 111235
      Bone cancer pain (BCP) is a type of ongoing or breakthrough pain caused by a primary bone tumor or bone metastasis. BCP impairs patients' quality of life. Depending upon clinical observations, the administration of centrally acting analgesic has been associated with the alleviation of pain symptoms BCP patients. Central nervous system sensitization performs a crucial role in pain-regulating perception in BCP. Nevertheless, the precise neural circuitry and mechanism of action remain enigmatic. In the present study, we observed the activation of glutamatergic neurons in the Prelimbic cortex (mPFC) and paraventricular thalamus (PVT) in BCP mice. Experimental validation using viral tracers confirmed the existence of a projection pathway between the PVT and mPFC. Inhibition of the input from PVT glutamatergic neurons to mPFC glutamatergic neurons alleviates chronic pain in BCP, whereas activation of the PVTGlu-mPFCGlu projection induces chronic pain in mice. These findings imply a pivotal role for the PVTGlu-mPFCGlu circuit in the regulation of chronic pain in BCP.
    Keywords:  Bone cancer pain; Glutamatergic neuron; Neural circuit; Paraventricular nucleus of the hypothalamus; Prelimbic cortex
    DOI:  https://doi.org/10.1016/j.brainresbull.2025.111235
  6. Mol Pain. 2025 Feb 08. 17448069251314738
      Patients with cancer perineural invasion (PNI) report greater spontaneous pain and mechanical allodynia. Here, we examine the impact of the disease on the peripheral sensory system, the excitability changes induced by PNI at the dorsal root ganglia, and the potential protective role of the absence of Tumor Necrosis Factor-α Receptor 1 (TNFR1). To study these effects, we use a murine model generated by injecting mouse oral cancer squamous cell carcinoma (MOC2) into the sciatic nerve (MOC2-PNI) in both male and female mice. We found that MOC2-PNI induces a profound change in the somatosensory landscape by deactivating/blocking the peripheral inputs while modulating the afferent's sensibility (tactile desensitization with concurrent nociceptive sensitization) and demyelination without inducing spontaneous activity. All these changes caused by MOC2-PNI are unmitigated by the absence of TNFR1. We conclude that MOC2-PNI induces an aberrant neuronal excitability state and triggers extreme gender-specific neuronal plasticity. These data allow us to speculate on the role of such plasticity as a powerful defense mechanism to prevent terminal sensory dysfunction, the rise of chronic pain, and extend animals' survivability.
    Keywords:  Cancer; MOC2; Nociception; PNI; Pain; Somatosensory system
    DOI:  https://doi.org/10.1177/17448069251314738
  7. Clin Lung Cancer. 2025 Jan 11. pii: S1525-7304(25)00007-5. [Epub ahead of print]
       BACKGROUND: Central nervous system (CNS) metastases are common among patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC). Osimertinib in combination with chemotherapy beyond osimertinib progression may minimize CNS progression.
    METHOD: In this retrospective analysis, patients with advanced EGFR mutation positive NSCLC and brain metastases who received platinum-based chemotherapy (PbChT) after disease progression on osimertinib were enrolled. The primary endpoint was real-world CNS progression-free survival (rwCNS-PFS) between patients who received PbChT with and without osimertinib continuation. Secondary endpoints included competing risk analysis of CNS progression and incidence of salvage radiotherapy to brain.
    RESULTS: A total of 101 patients were analyzed, out of which, 39 (39%) continued osimertinib with chemotherapy (OSI+ cohort) and 62 (61%) received chemotherapy alone (OSI- cohort). Median rwCNS-PFS was significantly longer in the OSI+ cohort (9.0 months, 95% CI 6.6-11.4) than the OSI- cohort (5.7 months, 95% CI 4.6-6.9) (HR 0.37, 95% CI 0.18-0.76, P = .007). This remained significant after adjustment for EGFR mutation, line of osimertinib treatment, prior radiotherapy to brain, and CNS progression on osimertinib monotherapy. Estimated probability of CNS progression at 6 months was 5.6% in OSI+ cohort versus 20.9% in OSI- cohort. Incidence of salvage radiotherapy to brain was lower in the OSI+ cohort (15%) compared to OSI- cohort (24%).
    CONCLUSION: In patients with EGFR mutation positive NSCLC and brain metastases, continuing osimertinib with chemotherapy after progression on osimertinib significantly reduced risk of CNS progression. Prospective studies are warranted to define the optimal treatment strategy for this patient population.
    Keywords:  Brain metastase
    DOI:  https://doi.org/10.1016/j.cllc.2025.01.007
  8. World J Gastroenterol. 2025 Feb 07. 31(5): 101280
       BACKGROUND: Gastrointestinal schwannomas (GIS) are rare neurogenic tumors arising from Schwann cells in the gastrointestinal tract. Studies on GIS are limited to small case reports or focus on specific tumor sites, underscoring the diagnostic and therapeutic challenges they pose.
    AIM: To comprehensively examine the clinical features, pathological characteristics, treatment outcomes, associated comorbidities, and prognosis of GIS.
    METHODS: The study population included patients diagnosed with GIS at the First Affiliated Hospital, Zhejiang University School of Medicine, between June 2007 and April 2024. Data were retrospectively collected and analyzed from medical records, including demographic characteristics, endoscopic and imaging findings, treatment modalities, pathological evaluations, and follow-up information.
    RESULTS: In total, 229 patients with GIS were included, with a mean age of 56.00 years and a male-to-female ratio of 1:1.83. The mean tumor size was 2.75 cm, and most (76.9%) were located in the stomach. Additionally, 6.6% of the patients had other malignant tumors. Preoperative imaging and endoscopy frequently misdiagnosed GIS as gastrointestinal stromal tumors. However, accurate preoperative diagnosis was achieved using endoscopic ultrasound-guided fine-needle aspiration combined with immunohistochemical analysis, in which S100 and SOX-10 markers were mostly positive. Smaller tumors were typically managed with endoscopic resection, while larger lesions were treated with surgical resection. Follow-up results showed that most patients experienced favorable outcomes.
    CONCLUSION: Preoperative diagnosis of GIS via clinical characteristics, endoscopy, and imaging examinations remains challenging but crucial. Endoscopic therapy provides a minimally invasive and effective option for patients.
    Keywords:  Complications; Diagnosis; Endoscopictherapy; Gastrointestinal schwannoma; Treatment
    DOI:  https://doi.org/10.3748/wjg.v31.i5.101280
  9. Mol Pain. 2025 Feb 13. 17448069251323666
      Preclinical studies addressing the peripheral effects of cancer perineural invasion report severe neuronal availability and excitability changes. Oral cell squamous cell carcinoma perineural invasion (MOC2-PNI) shows similar effects, modulating the afferent's sensibility (tactile desensitization with concurrent nociceptive sensitization) and demyelination without inducing spontaneous activity (see Part 1.). The current study addresses the electrical status (normal or abnormal) of both active (low threshold mechano receptors (LT) and high threshold mechano receptors (HT)) and inactive (F-type and S-type) afferents. Concurrently, we have also evaluated changes in the genetic landscape that may help to understand the physiological dynamics behind MOC2-PNI-induced functional disruption of the peripheral sensory system. We have observed that the altered cell distribution and mechanical sensibility of the animal's somatosensory system cannot be explained by cellular electrical dysfunction or MOC2-PNI-induced apoptosis. Although PNI does modify the expression of several genes related to cellular hypersensitivity, these changes are insufficient to explain the MOC2-PNI-induced aberrant neuronal excitability state. Our results indicate that genetic markers provide limited information about the functional hyperexcitable state of the peripheral system. Importantly, our results also highlight the emerging role of plasma membrane Ca2+-ATPase activity (PMCA) in explaining several aspects of the observed gender-specific neuronal plasticity and the reported cellular distribution switch generated by MOC2-PNI.
    Keywords:  Cancer; Gene expression; MOC2; Nociception; PNI; Pain; Somatosensory system
    DOI:  https://doi.org/10.1177/17448069251323666
  10. Int J Mol Sci. 2025 Jan 30. pii: 1229. [Epub ahead of print]26(3):
      The burden of cancer is growing in almost every country. Bone metastases significantly affect the prognosis and lead to an increase in mortality and morbidity. The management of cancer-induced bone pain (CIBP) still shows various unmet needs. Opioid use is burdened by a number of possible side effects. Moreover, recent progresses in cancer treatment significantly increased the life expectancy of cancer patients, even those with metastatic disease. In this narrative review, we reported the main findings regarding TRP channel function in cancer pain models. TRP cation channels play a key role in different functions of cancer cells, including the regulation of their potential for metastasization, and are the main channels involved in the pathways of pain perception, through peripheral and central effects. Genetic deletion decreased pain sensitivity following tumour cell inoculation. Preclinical data suggest a potential role for modulators of some TRP channels, such as TRPV1, TRPA1, TRPM7 and TRPM8. Clinical results are still scarce; however, the physiological role in modulating bone remodelling and the involvement of TRP channels in preclinical models of bone cancer pain have garnered interest as areas of research in the last few years, as innovative analgesic strategies that may overcome the long-term side effects of opioids.
    Keywords:  TRP channels; TRPA1; TRPM8; TRPV1; bone; cancer pain; metastasis; neuropathic pain; opioids; resiniferatoxin
    DOI:  https://doi.org/10.3390/ijms26031229
  11. J Oral Maxillofac Pathol. 2024 Oct-Dec;28(4):28(4): 651-656
      Hybrid peripheral nerve sheath tumours (PNSTs) are mainly benign, which represent combined areas of neurofibroma, schwannoma, and perineurioma in various combinations and pose challenges to the surgeon and the pathologist. They are relatively new in pathology and were first published in the fourth edition of World Health Organization Classification of Tumors of Soft tissue and Bone in 2013. They are mainly dermal or subcutaneous, and the most common variant of hybrid nerve sheath tumour is perineurioma-schwannoma. The combination of neurofibroma/schwannoma usually has an increased frequency with neurofibromatosis (NF) type 1 or 2 and schwannomatosis. In contrast, neurofibroma/perineurioma, mainly associated with NF1, are rare. Diagnosis is established by histopathology and immunohistochemistry. Hence, they embark diagnostic challenge and demand extreme vigilance and caution. However, the molecular pathogenesis, recurrence rates, and risk of malignant transformation of hybrid PNST remain poorly understood. A novel CHD7-VGLL3 fusion gene in a hybrid schwannoma-perineurioma and recurrent ERBB2 mutations in a subset of hybrid neurofibroma/schwannomas were identified. We have tried, via this article, to represent a brief update on hybrid nerve sheath tumours.
    Keywords:  Benign; Schwannoma; hybrid nerve sheath tumour; neurofibroma; perineurioma
    DOI:  https://doi.org/10.4103/jomfp.jomfp_126_24
  12. Zhonghua Zhong Liu Za Zhi. 2025 Feb 23. 47(2): 149-159
      Objective: To investigate the expression of Artemin (ARTN) in malignant peripheral nerve sheath tumor (MPNST), its effect on the malignant behavior of MPNST cells, and its signaling pathway. Methods: Fifty-one MPNST paraffin embedded tissues through surgical resection at Tianjin Medical University Cancer Hospital from January 1995 to November 2011 were collected, the expression of the ARTN protein was detected by immunohistochemistry, and the relationship between the ARTN protein expression and the clinical pathological characteristics and prognosis were analyzed. In human MPNST cell lines ST-8814 (NF-1) and STS26T(sporadic), ARTN overexpression and low expression cell lines were constructed by transfecting ARTN overexpression plasmids and ARTN small interfering RNA (siRNA), respectively. The expression of ARTN mRNA was detected by real time quantitative polymerase chain reaction (RT-qPCR), the expression of the ARTN protein and Phosphoinositide 3-kinase(PI3K)/Akt signaling pathway related proteins were detected by Western blot. CCK-8 assay was used to detect cell proliferation ability, and cell invasion assay was used to detect cell invasion ability. The pathway proteins that interacted with ARTN were searched in the STRING database, and the functional pathways were clarified by Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. The PI3K/Akt pathway specific inhibitor LY294002 was used to block the PI3K/Akt pathway of ST-8814 and STS26T cells to observe the changes in cell proliferation and invasion. Results: Among the 51 MPNST tissue specimens, 22 cases showed a high expression of the ARTN protein and 29 cases showed a low expression of the protein. Higher expressions of the ARTN protein was associated with larger tumor diameters and disease progression (recurrence or metastasis) (both P<0.05). The median disease-free survival (DFS) of patients with a low expression of the ARTN protein was 26.2 months, and the median overall survival (OS) was 66.9 months. The median DFS and median OS of patients with a high expression of the ARTN protein were 10.7 months and 53.8 months, respectively. The log rank test results showed that the progression free survival rate of patients with a high expression of the ARTN protein was worse than that of patients with a low expression (P=0.027), but the difference in overall survival rate between the two groups was not statistically significant (P=0.790), which was also confirmed by Cox regression analysis. The CCK-8 assay results showed that after 48 hours of transfection, the absorbance (A) values of ST-8814 and STS26T cells in the ARTN overexpression group were 1.35±0.01 and 1.10±0.02, respectively, which were higher than those in the empty plasmid control group (1.05±0.01 and 0.78±0.01, both P<0.01), while the A values of ST-8814 and STS26T cells in the ARTN siRNA group were 0.35±0.01 and 0.61±0.01, respectively, which were lower than those in the control siRNA group (0.74±0.01 and 1.10±0.04, both P<0.01). The results of cell invasion assay showed that the number of transmembrane cells in ST-8814 and STS26T cells overexpressing ARTN was (29.67±2.08) and (31.67±2.08), respectively, which were higher than those in the empty plasmid control group [(20.00±1.00) and (24.33±1.15), both P<0.01]. The number of transmembrane cells in ST-8814 and STS26T cells in the ARTN siRNA group were (14.00±2.00) and (19.33±1.53), respectively, which were lower than those in the control siRNA group [(19.33±2.52) and (23.33±0.58), both P<0.05].The KEGG results showed that ARTN is associated with multiple tumor signaling pathways, especially the PI3K/Akt signaling pathway. Western blot results showed that overexpression of ARTN upregulated the expression of p-PI3K and p-Akt proteins in ST-8814 and STS26T cells (both P<0.01).After knocking down ARTN expression, the expression of p-PI3K and p-Akt proteins was significantly down regulated (both P<0.01). LY294002 could significantly inhibit the effect of ARTN overexpression on ST-8814 and STS26T cells after blocking the PI3K/Akt pathway. The A values of ST-8814 and STS26T cells in the ARTN overexpression+LY294002 group were 1.09±0.06 and 0.82±0.01, respectively, which were lower than those in the ARTN overexpression group (1.50±0.01 and 1.29±0.01, respectively, both P<0.01). The numbers of transmembrane cells in the cell invasion assay were 16.67±3.21 and 19.67±2.31, respectively, which were also lower than those in the ARTN overexpression group (29.67±2.08 and 31.67±2.08, respectively, both P<0.01). Conclusions: In MPNST, a high expression of the ARTN protein was associated with larger tumor size, disease progression, and worse DFS. ARTN promotes the proliferation and invasion of MPNST cells through the PI3K/Akt signaling pathway.
    DOI:  https://doi.org/10.3760/cma.j.cn112152-20240531-00229
  13. Ann Hematol. 2025 Feb 12.
      Peripheral nervous system involvement in lymphoproliferative diseases, often due to direct nerve infiltration (neurolymphomatosis, NL), is mostly seen in aggressive B-cell lymphoma. We report the case of an 88-year-old man with stage IVA DLBCL, who achieved the first complete response after six R-miniCHOP21 cycles. One year post-treatment, he developed severe neurological symptoms, and PET-CT revealed widespread relapse with extensive neural involvement. Treatment with tafasitamab and lenalidomide led to a complete morpho-metabolic remission and full neurological recovery, with minimal side effects. This case underscores for the very first time the efficacy and tolerability of this regimen in treating NL, highlighting its potential for frail patients unfit for more intensive therapies.
    Keywords:  DLBCL; Lenalidomide; Neurolymphomatosis; Tafasitamab
    DOI:  https://doi.org/10.1007/s00277-025-06184-6
  14. Gan To Kagaku Ryoho. 2024 Dec;51(13): 1413-1415
      Gastric schwannoma is a rare primary gastric tumor, with several reports of malignancy. We report the case of a 76-year-old woman and conducted a literature review. The patient complained of epigastric pain and was referred to our gastroenterology department by a local doctor. Upper gastrointestinal endoscopy revealed a 30 mm submucosal tumor in the greater curvature of the middle part of the stomach. Endoscopic ultrasound-guided fine-needle aspiration was performed, and immunohistochemical staining confirmed the diagnosis of gastric schwannoma. Abdominal contrast computed tomography revealed the swelling in the surrounding lymph nodes, and fludeoxyglucose F18(FDG)positron emission tomography showed FDG accumulation in the primary lesion. Although biopsy confirmed that the tumor was a schwannoma, not a gastrointestinal tumor or another malignant tumor, laparoscopic radical distal gastrectomy with D2 lymph node dissection was performed. The postoperative course was uneventful, and the patient was discharged on the 10th postoperative day. Histopathological diagnosis showed no lymph node metastasis, but the MIB-1 index was high(10.9%), indicating a diagnosis of high-grade malignant schwannoma. The patient has been undergoing outpatient follow-up for approximately 2 years without recurrence. Gastric schwannoma is a rare primary gastric tumor, and radical surgical procedures should be carefully considered. Further collection and analysis of these cases are necessary in the future.